News

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The

Narcan was the first naloxone product approved by the U.S. Food and Drug Administration (FDA) as a treatment for opioid overdose in 1971. Narcan has not been distributed

The trial is a follow-on study to a first Phase I/IIa study completed in 2014, enrolling 26 patients. Functioning as their own placebo, all patients were subjected to

As part of the deal, Glycotope will be Cantargia’s production partner to obtain material for the clinical studies of CAN04 in cancer patients. The deal will also see

The trial is being carried out by clinicians at Cedars-Sinai, Los Angeles, who were awarded a grant from The National Institute of Diabetes and Digestive and Kidney Diseases

Following discussions with the US Food and Drug Administration (FDA), the company has finalized its clinical protocol and intends to begin patient enrollment within the next month at

Galderma gets FDA nod to market Restylane Lyft with lidocaine for age related volume loss in cheek area. Previously marketed as Perlane-L, Restylane Lyft is an injectable gel

Orkambi is only indicated for these patients, who can be identified with a genetic test. The company said that Orkambi will be available for shipment to specialty pharmacies

Last year, the Russian pharmaceutical market recorded RUB765bn ($13.6bn) in sales, according to IMS Health. Biocom mainly focuses on therapies such as cardiovascular, central nervous system (CNS) and